The Loss of BKV-specific Immunity from Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication

American Journal of Transplantation

Volumn 15, Issue 8, 2015, Pages 2159-2169

  Schachtner, T ^a,b   Stein, M ^b   Babel, N ^a,b   Reinke, P ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Brandenburg Center for Regenerative Therapies   (Germany)

Author keywords

alloantigen; basic (laboratory) research science; clinical research practice; immunosuppression immune modulation; infection and infectious agents; infectious disease; kidney transplantation nephrology; T cell biology; viral: BK JC polyoma; viral: Cytomegalovirus (CMV)

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CIDOFOVIR; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS DNA; VIRUS LARGE T ANTIGEN;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ADULT; AGED; ALLOIMMUNITY; ANTIVIRAL THERAPY; ARTICLE; BK VIRUS; BK VIRUS INFECTION; BLOOD GROUP ABO INCOMPATIBILITY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT RECIPIENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MALE; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; ADVERSE EFFECTS; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; VIRUS INFECTION;

ADULT; AGED; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; VIRUS DISEASES; VIRUS REPLICATION;

EID: 84937401996     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13252     Document Type: Article

References (31)

1. Hirsch HH, Steiger J,. Polyomavirus BK. Lancet Infect Dis 2003; 3: 611-623.
2. Ramos E, Drachenberg CB, Papadimitriou JC, et al., Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145-2151.
3. Wadei HM, Rule AD, Lewin M, et al., Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 2006; 6: 1025-1032.
4. Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A,. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant 2010; 10: 2324-2330.
5. Babel N, Volk HD, Reinke P,. BK polyomavirus infection and nephropathy: The virus-immune system interplay. Nat Rev Nephrol 2011; 24: 399-406.
6. Hirsch HH, Vincenti F, Friman S, et al., Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: A prospective, randomized, multicenter study. Am J Transplant 2013; 13: 136-145.
7. Nickeleit V, Hirsch HH, Binet IF, et al., Polyomavirus infection of renal allograft recipients: From latent infection to manifest disease. J Am Soc Nephrol 1999; 10: 1080-1089.
8. Nickeleit V, Klimkait T, Binet IF, et al., Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309-1315.
9. Hirsch HH, Knowles W, Dickenmann M, et al., Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488-496.
10. Babel N, Fendt J, Karaivanov S, et al., Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: Analysis of 4128 urine and serum samples. Transplantation 2009; 88: 89-95.
11. Schachtner T, Müller K, Stein M, Sefrin A, Babel N, Reinke P,. BKV-Specific immunity kinetics: A predictor of recovery from BKV-associated nephropathy. Am J Transplant 2011; 11: 2443-2452.
12. Schachtner T, Stein M, Sefrin A, Babel N, Reinke P,. Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV-replication after renal transplantation. Transplant Int 2014; 27: 290-301.
13. Müller K, Schachtner T, Sattler A, et al., BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation 2011; 91: 100-107.
14. Binggeli S, Egli A, Schaub S, et al., Polyomavirus BK-specific cellular immune response to VP1 and Large T-Antigen in kidney transplant recipients. Am J Transplant 2007; 7: 1131-1139.
15. Comoli P, Binggeli S, Ginevri F, Hirsch HH,. Polyomavirus-associated nephropathy: Update on BK virus-specific immunity. Transpl Infect Dis 2006; 8: 86-94.
16. Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S,. Recovery of BK virus Large T-antigen-specific cellular immune response correlates with resolution of BK virus nephritis. Transplantation 2008; 85: 185-192.
17. Comoli P, Hirsch HH, Ginevri F,. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008; 13: 569-574.
18. Comoli P, Basso S, Azzi A, et al., Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003; 14: 3197-3204.
19. Hammer MH, Brestrich G, Andree H, et al., HLA type-independent method to monitor polyoma BK virus-specific CD4+ and CD8+ T-Cell immunity. Am J Transplantation 2006; 6: 625-631.
20. Borni-Duval C, Caillard S, Olagne J, et al., Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation 2013; 95: 1498-1505.
21. Comoli P, Basso S, Hirsch H, et al., Humoral and cellular immunity to polyomavirus BK large T and VP1 antigens after pediatric kidney transplantation. 2008; 8: supplement 2, article 283.
22. Racusen LC, Colvin RB, Solez K, et al., Antibody-mediated rejection criteria-An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
23. Bestard O, Crespo E, Stein M, et al., Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 2013; 13: 1880-1890.
24. Comoli P, Cioni M, Basso S, et al., Immunity to polyomavirus BK infection: Immune monitoring to regulate the balance between risk of BKV nephropathy and induction of alloimmunity. Clin Dev Immunol 2013; 2013: 256923.
25. Blyth E, Clancy L, Simms R, et al., BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation 2011; 92: 1077-1084.
26. Bohl DL, Storch GA, Ryschkewitsch C, et al., Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5: 2213-2221.
27. Shah KV,. Human polyomavirus BKV and renal disease. Nephrol Dial Transplant 2000; 15: 754-755.
28. Sood P, Senanayake S, Sujeet K, et al., Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: A prospective single-center study. Transplantation 2013; 95: 896-902.
29. Schmitt C, Raggub L, Linnenweber-Held S, Adams O, Schwarz A, Heim A,. Donor origin of BKV replication after kidney transplantation. J Clin Virol 2014; 59: 120-125.
30. Millán O1, Rafael-Valdivia L, Torrademé E, et al., Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine 2013; 61: 556-564.
31. Hirsch HH, Ramos E,. Retransplantation after polyomavirus-associated nephropathy: Just do it? Am J Transplant 2006; 6: 7-9.